Silver Book Fact

Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections

Bressler N, Chang T, Fine J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmol. 2010; 117(4). http://www.aaojournal.org/article/S0161-6420(09)00981-6/abstract

Reference

Title
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR
Publication
Ophthalmol
Publication Date
2010
Authors
Bressler N, Chang T, Fine J, et al
Volume & Issue
Volume 117, Issue 4
Pages
747-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.  
  • High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).